Ultragenyx Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY24 revenue guidance above estimates. Also, Cantor Fitzgerald and Wedbush raised their respective price targets on the stock.
Portfolio Pulse from Benzinga Newsdesk
Ultragenyx Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY24 revenue guidance above estimates. Additionally, Cantor Fitzgerald and Wedbush raised their respective price targets on the stock.
August 02, 2024 | 4:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ultragenyx Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY24 revenue guidance above estimates. Cantor Fitzgerald and Wedbush also raised their price targets on the stock.
The better-than-expected Q2 financial results and raised FY24 revenue guidance are positive indicators for Ultragenyx Pharmaceuticals. Additionally, the increased price targets from Cantor Fitzgerald and Wedbush further boost investor confidence, likely driving the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100